DE69934881D1 - Selective il-2 agonisten und antagonisten - Google Patents

Selective il-2 agonisten und antagonisten

Info

Publication number
DE69934881D1
DE69934881D1 DE69934881T DE69934881T DE69934881D1 DE 69934881 D1 DE69934881 D1 DE 69934881D1 DE 69934881 T DE69934881 T DE 69934881T DE 69934881 T DE69934881 T DE 69934881T DE 69934881 D1 DE69934881 D1 DE 69934881D1
Authority
DE
Germany
Prior art keywords
agonists
antagonists
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934881T
Other languages
English (en)
Other versions
DE69934881T2 (de
Inventor
B Shanafelt
M Greve
Gary Jesmok
J Lembach
D Wetzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of DE69934881D1 publication Critical patent/DE69934881D1/de
Application granted granted Critical
Publication of DE69934881T2 publication Critical patent/DE69934881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69934881T 1998-05-15 1999-05-13 Selective il-2 agonisten und antagonisten Expired - Lifetime DE69934881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
US80080 1998-05-15
PCT/US1999/010643 WO1999060128A1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (2)

Publication Number Publication Date
DE69934881D1 true DE69934881D1 (de) 2007-03-08
DE69934881T2 DE69934881T2 (de) 2007-11-08

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934881T Expired - Lifetime DE69934881T2 (de) 1998-05-15 1999-05-13 Selective il-2 agonisten und antagonisten

Country Status (39)

Country Link
EP (1) EP1076704B1 (de)
JP (1) JP4276783B2 (de)
KR (1) KR100607609B1 (de)
CN (2) CN101319247B (de)
AR (1) AR020322A1 (de)
AT (1) ATE351907T1 (de)
AU (1) AU759697B2 (de)
BG (1) BG65139B1 (de)
BR (1) BRPI9910504B1 (de)
CA (1) CA2327349C (de)
CO (1) CO5070701A1 (de)
CU (2) CU23273B7 (de)
CY (1) CY1107533T1 (de)
CZ (1) CZ302071B6 (de)
DE (1) DE69934881T2 (de)
DK (1) DK1076704T3 (de)
DZ (1) DZ2788A1 (de)
ES (1) ES2281175T3 (de)
HK (1) HK1039963B (de)
HN (1) HN1999000075A (de)
HU (1) HU226142B1 (de)
IL (2) IL139136A0 (de)
MY (1) MY130274A (de)
NO (1) NO329235B1 (de)
NZ (1) NZ508098A (de)
PA (1) PA8472601A1 (de)
PE (1) PE20000475A1 (de)
PL (1) PL201675B1 (de)
PT (1) PT1076704E (de)
RO (1) RO122150B1 (de)
RU (1) RU2235729C2 (de)
SI (1) SI20643B (de)
SK (1) SK288100B6 (de)
SV (1) SV1999000061A (de)
TN (1) TNSN99090A1 (de)
TR (1) TR200003354T2 (de)
TW (1) TWI223663B (de)
UA (1) UA73719C2 (de)
WO (1) WO1999060128A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
SI1682180T1 (sl) 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
EP1718670B1 (de) * 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
IL295201A (en) 2010-11-12 2022-10-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
EP2655409A4 (de) 2010-12-22 2015-07-01 Univ Leland Stanford Junior Superagonisten und antagonisten von interleukin-2
PE20181077A1 (es) 2011-02-10 2018-07-05 Roche Glycart Ag Polipeptidos interleuquina-2-mutantes
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
NZ760289A (en) 2014-02-06 2023-05-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3134102B1 (de) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonisten, partielle agonisten und antagonisten von interleukin-2
HUE051414T2 (hu) * 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20200316118A1 (en) * 2016-05-19 2020-10-08 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3471753A1 (de) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1- und il-2-zytokine
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11648271B2 (en) * 2016-06-22 2023-05-16 David Klatzmann Genetically modified T lymphocytes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
AU2017359172A1 (en) 2016-11-08 2019-05-16 Delinia, Inc. IL-2 variants for the treatment of autoimmune diseases
MX2019007002A (es) * 2016-12-13 2019-08-22 Delinia Inc Moduladores de linfocitos t reguladores multivalentes.
EP3596108A4 (de) 2017-03-15 2020-12-23 Pandion Operations, Inc. Gezielte immuntoleranz
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
EP3630162A1 (de) * 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin-gepfropfte proteine und verfahren zur verwendung
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2019028419A1 (en) * 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
KR20200086722A (ko) * 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
JP2021519336A (ja) 2018-03-28 2021-08-10 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ−２コンジュゲート
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020020783A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR102201086B1 (ko) * 2018-09-17 2021-01-11 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
BR112021010983A2 (pt) 2018-12-21 2021-08-31 Jiangsu Hengrui Medicine Co., Ltd. Variante de interleucina-2 humana ou seu derivado
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
US20220289807A1 (en) * 2019-08-13 2022-09-15 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof
JP7303391B2 (ja) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド バイアス型ｉｌ２ムテイン、方法、および組成物
CA3175717A1 (en) 2020-03-19 2021-09-23 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 mutant and use thereof
JP2023515247A (ja) * 2020-03-31 2023-04-12 ハンミ ファーマシューティカル カンパニー リミテッド 新規な免疫活性インターロイキン２アナログ
BR112022022826A2 (pt) 2020-06-03 2022-12-13 Ascendis Pharma Oncology Div A/S Sequências de il-2 e usos das mesmas
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
JP2023548311A (ja) 2020-10-29 2023-11-16 ブリストル－マイヤーズ スクイブ カンパニー 疾患の治療のための融合タンパク質
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
AU2022360645A1 (en) 2021-10-06 2024-05-02 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs with targeting specificity to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
US20240076343A1 (en) * 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
FR3140287A1 (fr) 2022-10-03 2024-04-05 Arkema France Procede de granulation de composes azoiques et granules obtenus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
NO20005762L (no) 2001-01-11
JP4276783B2 (ja) 2009-06-10
IL139136A (en) 2009-05-04
CA2327349A1 (en) 1999-11-25
DK1076704T3 (da) 2007-03-12
JP2002515247A (ja) 2002-05-28
SI20643A (sl) 2002-02-28
PE20000475A1 (es) 2000-07-07
HU226142B1 (en) 2008-05-28
ATE351907T1 (de) 2007-02-15
HK1039963A1 (en) 2002-05-17
WO1999060128A1 (en) 1999-11-25
HK1039963B (zh) 2008-09-05
KR100607609B1 (ko) 2006-08-02
RU2235729C2 (ru) 2004-09-10
DE69934881T2 (de) 2007-11-08
SK288100B6 (sk) 2013-07-02
CN101319247A (zh) 2008-12-10
NO20005762D0 (no) 2000-11-14
CU23273B7 (es) 2008-04-09
AR020322A1 (es) 2002-05-08
SK17242000A3 (sk) 2001-07-10
CN1309705A (zh) 2001-08-22
PL201675B1 (pl) 2009-04-30
RO122150B1 (ro) 2009-01-30
DZ2788A1 (fr) 2003-12-01
BG65139B1 (bg) 2007-03-30
CZ302071B6 (cs) 2010-09-29
EP1076704B1 (de) 2007-01-17
PL344407A1 (en) 2001-11-05
HUP0101948A2 (hu) 2001-09-28
CU23272A1 (es) 2008-04-09
PT1076704E (pt) 2007-02-28
AU759697B2 (en) 2003-04-17
TR200003354T2 (tr) 2001-03-21
ES2281175T3 (es) 2007-09-16
KR20010043602A (ko) 2001-05-25
UA73719C2 (en) 2005-09-15
AU4078499A (en) 1999-12-06
TNSN99090A1 (fr) 2005-11-10
MY130274A (en) 2007-06-29
CO5070701A1 (es) 2001-08-28
NO329235B1 (no) 2010-09-20
BG104929A (en) 2001-09-28
TWI223663B (en) 2004-11-11
HN1999000075A (es) 1999-09-29
CN100366742C (zh) 2008-02-06
EP1076704A1 (de) 2001-02-21
BRPI9910504B1 (pt) 2016-08-09
CA2327349C (en) 2010-10-26
BR9910504A (pt) 2001-01-09
PA8472601A1 (es) 2000-09-29
CY1107533T1 (el) 2013-03-13
NZ508098A (en) 2003-09-26
HUP0101948A3 (en) 2003-08-28
CN101319247B (zh) 2012-12-12
SV1999000061A (es) 2000-03-14
IL139136A0 (en) 2001-11-25
SI20643B (sl) 2008-02-29
CZ20004213A3 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
DE69934881D1 (de) Selective il-2 agonisten und antagonisten
NO20004778D0 (no) Amidderivater og nociceptin antagonister
DE69913169D1 (de) Sportschuh und dafür vorgesehene dornen
DE69921723D1 (de) USB-Vorrichtung und USB- Knotenpunktvorrichtung
DE69932265D1 (de) Musikaktionsspielsystem und computerlesbare Aufzeichnungsvorrichtung
DE69924002D1 (de) Kompressions-abgestimmtes bragggitter und kompressions-abgestimmter laser
DE69918107D1 (de) Ionomere und ionenleitende zusammensetzungen
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE69835697D1 (de) Bauteile-bestückungsvorrichtung und bauteile-zufuhrvorrichtung
DE69925068D1 (de) Netzwerk und Knoteneinrichtung
DE60014137D1 (de) Schneidewerkzeug und werkzeughaltevorrichtung
DE60031119D1 (de) Richtbohrvorrichtung und -verfahren
DE19983830T1 (de) Schneid-Vorrichtung
ATE227724T1 (de) Muscarinagonisten und antagonisten
DE69933476D1 (de) Fluorelastomer und vernetzbare zusammensetzung daraus
DE50015227D1 (de) Packung und Zuschnitt
ATE295839T1 (de) N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
DE69921110D1 (de) Bohrflüssigkeiten und zusatzstoffen
DE69905644D1 (de) Fördermatte und Fördervorrichtung
DE69805154D1 (de) Programmierbares Gerät
NO963331D0 (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
DE69921206D1 (de) Oszillator und Kommunikationsgerät
ATE231489T1 (de) N-sulphonyl und n-sulphinyl phenylglycinamide
DE29807261U1 (de) Schneidvorrichtung
ATE272118T1 (de) T-zell selektive interleukin-4 agoniste

Legal Events

Date Code Title Description
8364 No opposition during term of opposition